Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  van der Horst, Paul H ^a   Wang, Yongyi ^a   Vandenput, Ingrid ^b   Kühne, Liesbeth C ^a   Ewing, Patricia C ^a   van IJcken, Wilfred F J ^a   van der Zee, Marten ^a   Amant, Frederic ^b   Burger, Curt W ^a   Blok, Leen J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PARAFFIN; PROGESTERONE; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; VIMENTIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; BETA CATENIN GENE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL LOSS; CONTROLLED STUDY; CXCL14 GENE; DISEASE ASSOCIATION; DKK1 GENE; DKK4 GENE; DOWN REGULATION; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; INTERLEUKIN 6 GENE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; METASTASIS; MIGRATION INHIBITION; ONCOGENE; PEG10 GENE; PROTEIN EXPRESSION; RECURRENT CANCER; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE CHARACTERIZATION; TRANSFORMING GROWTH FACTOR BETA GENE; UPREGULATION; WIF1 GENE; WNT SIGNALING PATHWAY; CELL MOTION; DISEASE COURSE; DRUG EFFECT; ENDOMETRIUM TUMOR; GENETICS; GENOMICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENOMICS; HUMANS; MIDDLE AGED; PROGESTERONE; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; TRANSCRIPTOME;

EID: 84856247112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030840     Document Type: Article

References (61)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127: 2893-2917.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, et al. (2005) Endometrial cancer. Lancet 366: 491-505.
3. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300.
4. Cohn DE, Horowitz NS, Mutch DG, Kim S-M, Manolitsas T, et al. (2002) Should the Presence of Lymphvascular Space Involvement Be Used to Assign Patients to Adjuvant Therapy Following Hysterectomy for Unstaged Endometrial Cancer? Gynecologic Oncology 87: 243-246.
5. Jolly S, Vargas CE, Kumar T, Weiner SA, Brabbins DS, et al. (2006) The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecologic Oncology 103: 87-93.
6. Kosary CL, (1994) FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10: 31-46.
7. Lindauer J, Fowler JM, Manolitsas TP, Copeland LJ, Eaton LA, et al. (2003) Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer? Gynecologic Oncology 91: 547-551.
8. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, et al. (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77: 1303-1310.
9. de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Löwik MJ, van der Hulst JM, et al. (2010) An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer. Cancer Research 70: 2707-2717.
10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
11. Hiraoka N, (2010) Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. International Journal of Clinical Oncology pp. 1-8.
12. Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ, (2009) Density of Tumor-Infiltrating Lymphocytes Correlates with Disease Recurrence and Survival in Patients with Large Non-Small-Cell Lung Cancer Tumors. J Surg Res.
13. Le DT, Ladle BH, Lee T, Weiss V, Yao X, et al. (2010) CD8+Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. International Journal of Cancer pp. n/a-n/a.
14. Leffers N, Fehrmann RSN, Gooden MJM, Schulze URJ, ten Hoor KA, et al. (2010) Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 103: 685-692.
15. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. New England Journal of Medicine 348: 203-213.
16. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67: 9518-9527.
17. de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AGJ, et al. (2009) Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecologic Oncology 114: 105-110.
18. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB, (2004) Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10: 4450-4456.
19. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM, (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158: 796-807.
20. Jeon Y-T, Park I-A, Kim Y-B, Kim JW, Park N-H, et al. (2006) Steroid receptor expressions in endometrial cancer: Clinical significance and epidemiological implication. Cancer Letters 239: 198-204.
21. Hanekamp EE, Gielen SC, Smid-Koopman E, Kuhne LC, de Ruiter PE, et al. (2003) Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 9: 4190-4199.
22. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ, (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Cancer 79: 320-327.
23. Yahata T, Fujita K, Aoki Y, Tanaka K, (2006) Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21: 1070-1075.
24. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, et al. (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17: 1736-1744.
25. Wang Y, Hanifi-Moghaddam P, Hanekamp EE, Kloosterboer HJ, Franken P, et al. (2009) Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 15: 5784-5793.
26. Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, et al. (2008) The Regulation and Function of the Forkhead Transcription Factor, Forkhead Box O1, Is Dependent on the Progesterone Receptor in Endometrial Carcinoma. Endocrinology 149: 1942-1950.
27. Scholten AN, Creutzberg CL, van den Broek L, Noordijk EM, Smit V, (2003) Nuclear β-catenin is a molecular feature of type I endometrial carcinoma. The Journal of Pathology 201: 460-465.
28. Tavassoli FA, Devilee P, (2003) World Health Organisation: Tumours of the Breast and Female Genital Organs (Classification of Tumours) IARCPress-WHO.
29. Pecorelli S, (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105: 103-104.
30. Smid-Koopman E, Kuhne LC, Hanekamp EE, Gielen SC, De Ruiter PE, et al. (2005) Progesterone-induced inhibition of growth and differential regulation of gene expression in PRA- and/or PRB-expressing endometrial cancer cell lines. J Soc Gynecol Investig 12: 285-292.
31. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
32. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 98: 5116-5121.
33. Kim JJ, Chapman-Davis E, (2010) Role of progesterone in endometrial cancer. Semin Reprod Med 28: 81-90.
34. Mokhtar NM, Cheng CW, Cook E, Bielby H, Smith SK, et al. (2010) Progestin regulates chemokine (C-X-C motif) ligand 14 transcript level in human endometrium. Mol Hum Reprod 16: 170-177.
35. Bruner-Tran KL, Eisenberg E, Yeaman GR, Anderson TA, McBean J, et al. (2002) Steroid and Cytokine Regulation of Matrix Metalloproteinase Expression in Endometriosis and the Establishment of Experimental Endometriosis in Nude Mice. J Clin Endocrinol Metab 87: 4782-4791.
36. Ace CI, Okulicz WC, (2004) Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase. Reprod Biol Endocrinol 2: 54.
37. Thiery JP, Acloque H, Huang RYJ, Nieto MA, (2009) Epithelial-Mesenchymal Transitions in Development and Disease. Cell 139: 871-890.
38. Allavena P, Germano G, Marchesi F, Mantovani A, (2011) Chemokines in cancer related inflammation. Experimental Cell Research In Press, Accepted Manuscript.
39. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, et al. (2006) Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology 147: 1097-1121.
40. Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, et al. (2003) The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 80 (Suppl 1): S29-34; discussion S35.
41. Avila DM, Zoppi S, McPhaul MJ, (2001) The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. J Steroid Biochem Mol Biol 76: 135-142.
42. Hanekamp EE, Gielen SC, De Ruiter PE, Chadha-Ajwani S, Huikeshoven FJ, et al. (2005) Differences in invasive capacity of endometrial cancer cell lines expressing different progesterone receptor isotypes: possible involvement of cadherins. J Soc Gynecol Investig 12: 278-284.
43. Hanekamp EE, Kuhne EC, Smid-Koopman E, de Ruiter PE, Chadha-Ajwani S, et al. (2002) Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur J Cancer 38 (Suppl 6): S71-72.
44. Yee DS, Tang Y, Li X, Liu Z, Guo Y, et al. (2010) The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 9: 162.
45. Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, et al. (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194: 701-704.
46. Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, et al. (2001) Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res 61: 2751-2758.
47. Hu C, Xiong J, Zhang L, Huang B, Zhang Q, et al. (2004) PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia. Cell Mol Immunol 1: 280-294.
48. Ip WK, Lai PB, Wong NL, Sy SM, Beheshti B, et al. (2007) Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett 250: 284-291.
49. Jie X, Lang C, Jian Q, Chaoqun L, Dehua Y, et al. (2007) Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene 26: 5741-5751.
50. Liu D-c, Yang Z-l, Jiang S, (2011) Identification of PEG10 and TSG101 as Carcinogenesis, Progression, and Poor-Prognosis Related Biomarkers for Gallbladder Adenocarcinoma. Pathology & Oncology Research pp. 1-8.
51. Wang X, Yuling H, Yanping J, Xinti T, Yaofang Y, et al. (2007) CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells. J Immunol 179: 2880-2888.
52. Kelly RW, Illingworth P, Baldie G, Leask R, Brouwer S, et al. (1994) Progesterone control of interleukin-8 production in endometrium and chorio-decidual cells underlines the role of the neutrophil in menstruation and parturition. Hum Reprod 9: 253-258.
53. Berry KK, Varney ML, Dave BJ, Bucana CD, Fidler IJ, et al. (2001) Expression of interleukin-8 in human metastatic endometrial carcinoma cells and its regulation by inflammatory cytokines. Int J Gynecol Cancer 11: 54-60.
54. Giangrande PH, McDonnell DP, (1999) The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 54: 291-313; discussion 313-294.
55. Giangrande PH, Pollio G, McDonnell DP, (1997) Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. J Biol Chem 272: 32889-32900.
56. Tetel MJ, Giangrande PH, Leonhardt SA, McDonnell DP, Edwards DP, (1999) Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. Mol Endocrinol 13: 910-924.
57. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP, (2000) The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20: 3102-3115.
58. Yang L, (2010) TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy. Curr Mol Med 10: 374-380.
59. Yang L, Pang Y, Moses HL, (2010) TGF-[beta] and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends in Immunology 31: 220-227.
60. Pfeifer M, Schirmer U, Geismann C, Schafer H, Sebens S, et al. (2010) L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol Biol 11: 64.
61. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, et al. (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642.